Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + ICP-248 versus orelabrutinib in relapsed/refractory marginal zone lymphoma
CTR20263780Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib, mesutoclax in marginal zone B-cell lymphoma (MZL), sponsored by Innovent Biologics. Started Oct 2026; status: active.
02
Drugs
orelabrutinibmesutoclax
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20263780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263780.